A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.

G, Jackson; P, Taylor; GM, Smith; R, Marcus; A, Smith; P, Chu; TJ, Littlewood; A, Duncombe; M, Hutchinson; AB, Mehta; SA, Johnson; P, Carey; MJ, MacKie; PS, Ganly; GE, Turner; M, Deane; S, Schey; J, Brookes; SM, Tollerfield; MP, Wilson

doi:10.1046/j.1365-2141.2001.02551.x

Public

A multicentre, open, non-comparative phase II study of a combination of fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor in relapsed and refractory acute myeloid leukaemia and de novo refractory anaemia with excess of blasts in transformation.

Shared by NobleBlocks on Jan 1, 2001 • 12:00 AM UTC

Authors:

Jackson G

Taylor P

Smith GM

Abstract

The primary objective of this study was to determine the complete remission (CR) rate achieved with the FLAG (fludarabine phosphate, cytarabine and granulocyte colony-stimulating factor) regimen in patients with relapsed or refractory acute myeloid leukaemia (AML) or de novo refractory anaemia with ...

Discussions